Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease.
Saved in:
| Title: | Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease. |
|---|---|
| Authors: | Singer D; GSK, Philadelphia, PA, USA. Electronic address: david.a.singer@gsk.com., La EM; GSK, Philadelphia, PA, USA., Dubois de Gennes C; GSK, London, United Kingdom., Graham J; RTI Health Solutions, LLC, Research Triangle Park, NC, USA., Grace M; RTI Health Solutions, LLC, Research Triangle Park, NC, USA., Biundo E; GSK, Wavre, Belgium., Verelst F; GSK, Wavre, Belgium. |
| Source: | Vaccine [Vaccine] 2026 Jun 25; Vol. 88, pp. 128770. Date of Electronic Publication: 2026 Jun 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
